Profiles of patients who may benefits of combination therapy with telmisartan, amlodipine and hydrochlorothiazide Review article
Article Sidebar
Main Article Content
Abstract
Optimal blood pressure control reduces cardiovascular risk, morbidity, and mortality. Most patients require combination antihypertensive therapy to achieve target blood pressure. The basic three medications in the initial treatment of hypertension are angiotensin receptor antagonists, calcium channel blockers, and thiazide diuretics. Combinations of medications can have a synergistic effect, and lower doses reduce the risk of adverse effects, which translates into treatment persistence. When selecting therapy, it is important to adjust the medication to the patient’s profile to achieve the greatest benefit. Combination therapy with telmisartan, amlodipine, and hydrochlorothiazide is recommended for patients at high cardiovascular risk, with metabolic syndrome, impaired carbohydrate metabolism, cognitive impairment, and osteoporosis.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO) Eur Heart J. 2024; 45(38): 3912-4018, http://doi.org/10.1093/eurheartj/ehae178.
3. Imenshahidi M, Roohbakhsh A, Hosseinzadeh H. Effects of telmisartan on metabolic syndrome components: a comprehensive review. Biomed Pharmacother. 2024; 171: 116169.
4. Dziwura J, Widecka K. Skuteczna prewencja incydentów sercowo-naczyniowych u pacjentów z grupy wysokiego ryzyka – nowe wskazanie dla telmisartanu. Arterial Hypertension. 2010; 14(4): 332-43.
5. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000; 102: 1503-10.
6. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004; 292: 2217-25.
7. Gaciąg Z. Połączenie telmisartanu z amlodipiną – miejsce w terapii hipotensyjnej. Arterial Hypertension. 2011; 15(3): 188-200.
8. Jeong HT, Sung HH, Lee JH et al. Relationship Between Calcium Channel Blockers Therapy and Cognitive Function Improvement in Cognitive Decline Patients with Cerebrovascular Disease. High Blood Press Cardiovasc Prev. 2022; 29(6): 595-600. http://doi.org/10.1007/s40292-022-00538-1.
9. Kishi T, Hirooka Y, Sunagawa K. Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin- related kinase B in hippocampus of hypertensive rats. J Cardiol. 2012; 60(6): 489-94.
10. Liu CH, Sung PS, Li YR et al. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study. PLoS Med. 2021; 18(7): e1003707. http://doi.org/10.1371/journal.pmed.1003707.
11. Zhang R, Yin H, Yang M et al. Advanced Progress of the Relationship Between Antihypertensive Drugs and Bone Metabolism. Hypertension. 2023; 80(11): 2255-64.
12. Wu J, Wang M, Guo C et al. Angiotensin receptor blocker is associated with a lower fracture risk: an updated systematic review and meta-analysis. Int J Clin Pract. 2022; 2022: 7581110. http://doi.org/10.1155/2022/7581110.
13. Caudarella R, Vescini F, Rizzoli E et al. The Effect of Thiazides on Bone Markers, Bone Mineral Density and Fractures. Clinic Rev Bone Miner Metab. 2015; 13: 173-84.
14. Feskanich D, Willett WC, Stampfer MJ et al. A Prospective Study of Thiazide Use and Fractures in Women. Osteoporosis Int. 1997; 7: 79-84.